Article Text
Abstract
Objective Patients undergoing single-ventricle palliation have experienced significant improvement in survival in the recent era. However, a substantial proportion of these patients undergo reoperations. We performed a review of the Australia and New Zealand (ANZ) Fontan Registry to determine the overall reintervention and reoperative burden in these patients.
Methods A retrospective longitudinal cohort study was performed using data from patients who underwent a Fontan operation between 1975 and 2016 from the ANZ Fontan Registry. The data obtained included Fontan operation, reinterventions and most recent follow-up status. We examined the type and timing of reinterventions and survival.
Results Of the 1428 patients identified, 435 (30%) underwent at least one reintervention after the Fontan operation: 110 patients underwent early reintervention and 413 underwent late reinterventions. Excluding Fontan conversion and transplantation, 220 patients underwent at least one interventional procedure and 209 patients underwent at least one reoperation. Fenestration closure and pacemaker-related procedures were the most common catheter and surgical interventions, respectively. The cumulative incidence of reintervention following Fontan was 23%, 37% and 55% at 10, 20 and 30 years, respectively. Survival and freedom from failure were worse in patients requiring later reintervention after Fontan surgery (51% vs 83% and 42% vs 69%, respectively at 30 years, p<0.001). This difference persisted after excluding pacemaker-related procedures (p<0.001). Operative mortality for non-pacemaker late reoperations after Fontan was 6%.
Conclusions A substantial proportion of Fontan patients require further intervention to maintain effective single-ventricle circulation. Patients undergoing reoperation after Fontan have higher rates of mortality and failure, despite intervention.
- congenital heart disease
- complex congenital heart disease
- fontan physiology
- congenital heart disease surgery
Statistics from Altmetric.com
Footnotes
Contributors All authors contributed to the production of this manuscript through various methods including: study design, data collection, data analysis, manuscript preparation, revisions and preparation of final manuscript and revisions.
Funding This work was supported by a National Health and Medical Research Council (NHMRC) Partnership grant (1076849). The Murdoch Children’s Research Institute received support through the Victorian Government’s Operational Infrastructure Support Program. Yd'U is a NHMRC Clinician Practitioner Fellow (1082186).
Disclaimer Yves d’Udekem is a consultant for Merck Sharpe & Dohme and Actelion. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.